- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- F-1 Registration statement (foreign)
- 3.1 Second Amended and Restated Memorandum and Articles of Association of Aptorum Group Limited
- 4.1 Specimen Ordinary Share Certificate
- 4.2 Form of Series a Convertible Promissory Note
- 10.1 Appointment Letter Between the Company and Ian Huen (Founder, Chief Executive Officer & Executive Director), Dated September 25, 2017
- 10.2 Employment Letter Between the Company and Sabrina Khan (Chief Financial Officer), Dated September 1, 2017
- 10.3 Addendum to Employment Letter Between Company and Sabrina Khan (Chief Financial Officer) Dated April 24, 2018
- 10.4 Appointment Letter Between the Company and Darren Lui (Chief Business Officer, President & Director), Dated September 25, 2017
- 10.5 Employment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated August 31, 2017
- 10.6 Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated September 25, 2017
- 10.7 Second Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated October 30, 2017
- 10.8 Third Addendum to Appointment Letter Between the Company and Clark Cheng (Chief Medical Officer & Director), Dated January 2, 2018
- 10.9 Appointment Letter Between the Company and Keith Chan (Chief Scientific Officer), Dated August 18, 2017
- 10.10 Appointment Letter Between the Company and Charles Bathurst (Independent Non-executive Director), Dated September 24, 2017
- 10.11 Appointment Letter Between the Company and Mirko Scherer (Independent Non-executive Director), Dated September 24, 2017
- 10.12 Employment Agreement Between the Company and Justin Wu (Independent Non-executive Director), Dated September 18, 2017
- 10.13 Employment Agreement Between the Company and Douglas Arner (Independent Non-executive Director), Dated February 13, 2018
- 10.14 Management Agreement Between the Company and Guardian Capital Management Limited, Dated March 1, 2017
- 10.15 Consulting Agreement Between the Company and Globoasia, LLC (Includes Provisions for the Appointment of Keith Chan As Chief Scientific Officer) Dated August 18, 2017
- 10.16 Management Agreement Between the Company and Aptus Capital Limited, Dated October 26, 2010
- 10.17 First Addendum to the Management Agreement Between the Company and Aptus Capital Limited, Dated February 10, 2012
- 10.18 Second Addendum to the Management Agreement Between the Company and Aptus Capital Limited, December 9, 2016
- 10.19 Subscription Agreement Between the Company and Peace Range Limited, Dated April 6, 2018
- 10.20 Share Charge Agreement Between the Company, Jurchen Investment Corporation and Peace Range Limited, Dated April 25, 2018
- 10.21 Deed of Guarantee of Jurchen Investment Corporation, Acknowledged by Peace Range Limited, Dated April 25, 2018
- 10.22 Charge Account Agreement Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.23 Bond Certificate Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.24 Escrow Agreement Between the Company and Peace Range Limited, Dated April 25, 2018
- 10.25 2017 Share Option Plan
- 10.26 Form of Securities Purchase Agreement for the Series a Convertible Promissory Notes, Dated May 15, 2018
- 10.27 Lock-up Agreement for Series a Convertible Promissory Notes, Dated May 15, 2018
- 10.28 Exclusive License Agreement for NLS-1 Dated July 3, 2017
- 10.29 Addendum to License Agreement for NLS-1 Dated February 9, 2018
- 10.30 Exclusive Patent License Agreement for ALS-1
- 10.31 First Amendment to the Exclusive Patent License Agreement for ALS-1 Dated June 7, 2018
- 10.32 Exclusive Patent License Agreement for ALS-4
- 10.33 First Amendment to the Exclusive Patent License Agreement Dated June 7, 2018
- 10.34 Sub-tenancy Agreement for Guangdong Investment Tower
- 10.35 Service Agreement Between Covar Pharmaceuticals Incorporated and Videns Incorporation Limited Dated May 15, 2017
- 10.36 Appointment Letter and Addendum to Service Agreement with Covar Pharmaceuticals Incorporated and DR. Kwok Chow Dated December 15, 2017
- 10.37 Appointment Letter and Addendum to Service Agreement with Covar Pharmaceuticals Incorporated and MR. Austin Freedman Dated December 26, 2017
- 14.1 Code of Business Conduct and Ethics of the Company
- 21.1 List of Subsidiaries
- 23.1 Consent of Marcum Bernstein & Pinchuk LLP
- 99.1 Charter of the Audit Committee
- 99.2 Charter of the Compensation Committee
- 99.3 Charter of the Nominating and Corporate Governance Committee
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
We consent to the inclusion in this Registration Statement of Aptorum Group Limited (formally known as APTUS Holdings Limited and STRIKER ASIA OPPORTUNITIES FUND CORPORATION, the “Company”) on Form F-1 of our report dated July 13, 2018, with respect to our audits of the statements of net assets (predecessor basis) including the schedule of portfolio investments of the “Company” as of December 31, 2016 and February 28, 2017, and the related statements (predecessor basis) of operations, changes in net assets, and cash flows for the year ended December 31, 2016, the statements (predecessor basis) of operations, changes in net assets, and cash flows for the period January 1, 2017 through February 28, 2017, the consolidated balance sheet (successor basis) as of December 31, 2017, the related consolidated statements (successor basis) of operations and comprehensive loss, stockholders’ equity and cash flows for the period March 1, 2017 through December 31, 2017, and the related notes (collectively referred to as the “financial statements”), which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum Bernstein & PinchukLLP
Marcum Bernstein & PinchukLLP
New York, New York
September 4, 2018
NEW YORK OFFICE• 7 Penn Plaza• Suite 830• New York, New York 10001• Phone 646.442.4845• Fax 646.349.5200• marcumbp.com